Objectives: The incidence and mortality from colorectal cancer among whites have decreased, but they have remained unchanged among African Americans. To explain this disparity, we used the multicenter endoscopy database of the Clinical Outcomes Research Initiative to compare the prevalence of proximal polyps and tumors among asymptomatic African Americans and whites undergoing routine screening colonoscopy.
Methods: African Americans and whites undergoing colonoscopy between January 1, 2002 and September 30, 2003 were considered for analysis.
Results: There were 145,175 index colonoscopy reports on unique patients. After applying exclusion criteria, 46,726 patients remained for analysis. Adjusting for age, gender, American Society of Anesthesiologists level, bowel preparation and endoscopic setting, African Americans were less likely to have polyps [adjusted odds ratio (OR) = 0.77; 95% confidence interval (CI) = 0.70-0.84]. However, the odds of having proximal polyps was higher in African Americans (OR = 1.30; 95% CI: 1.11-1.52) compared to whites. In regards to tumors, African Americans were more likely to have tumors (OR = 1.78; 95% CI: 1.14-2.77) and more likely to have proximal tumors than whites (OR = 4.37; 95% CI: 1.16-16.42).
Conclusions: After adjusting for confounders, African Americans undergoing screening colonoscopy in multiple practice settings had higher odds of proximal polyps and tumors than whites, suggesting current colorectal cancer screening recommendations in African Americans should be expanded.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2574351 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Patterns in mortality associated with heart failure and lung cancer among older adults in the United States: An analysis of 20 years.
Int J Cardiol Cardiovasc Risk Prev
March 2025
College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland.
Background: Despite an established association between heart failure (HF) and lung cancer (LC), there is limited evidence available regarding mortality patterns among the older (≥65 years) population in the United States.
Methods: The mortality data, spanning 1999 to 2019, was surveyed using the Centers for Disease Control and Prevention's Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database with HF and LC identified as underlying or contributing causes of death. Crude and age-adjusted mortality rates (AAMR) were calculated per 100,000 individuals.
General social support is commonly studied as a psychosocial resource that improves African Americans' well-being; we know less about how varied indicators of social support influence African Americans' depressive symptoms. Further, it is unclear how social support affects depressive symptoms differently when considering the moderating role of education. Using the National Survey of American Life (NSAL) (n = 3,278), we examined (1) the association between educational attainment and depressive symptoms, (2) the association between social support and depressive symptoms, and (3) whether education moderates the social support-depressive symptoms relationship among African Americans.
View Article and Find Full Text PDFBackground: Belzutifan, a first-in-class HIF-2α inhibitor, has shown antitumour activity as monotherapy and in combination with cabozantinib in patients with previously treated advanced kidney cancer. The phase 2 LITESPARK-003 study was designed to determine the antitumour activity and safety of belzutifan in combination with cabozantinib in patients with advanced clear-cell renal cell carcinoma that was previously untreated (cohort 1) or previously treated with immunotherapy (cohort 2). Here, we report results from cohort 1 of this clinical trial.
View Article and Find Full Text PDFVanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Lancet Respir Med
December 2024
Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:
Background: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor-tezacaftor-deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 6-11 years.
View Article and Find Full Text PDFGod Knows Best: Exploring the God Locus of Health Control, Race-Ethnicity, and Risk-Taking and Protective Behaviors Interrelationship in the USA.
J Relig Health
January 2025
Department of Sociology and Demography, The University of Texas at San Antoni, San Antonio, TX, USA.
The health implications of engaging in risk-taking or protective behaviors can have long-lasting effects on an individual's life. In recent years, there has been a growing interest in how religious attitudes and beliefs influence an individual's health behaviors. However, research on the role of the God Locus of Health Control (GLHC) in the religion-health literature is lacking.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!